Insider Buying: Daxor Co. (NASDAQ:DXR) CEO Acquires 3,360 Shares of Stock

Daxor Co. (NASDAQ:DXR) CEO Michael Richard Feldschuh purchased 3,360 shares of the company’s stock in a transaction dated Monday, March 10th. The stock was purchased at an average price of $7.68 per share, with a total value of $25,804.80. Following the completion of the purchase, the chief executive officer now directly owns 210,852 shares in the company, valued at $1,619,343.36. The trade was a 1.62 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Daxor Stock Performance

Shares of DXR opened at $8.16 on Friday. Daxor Co. has a 52 week low of $6.55 and a 52 week high of $10.00. The stock has a fifty day moving average of $7.77 and a 200-day moving average of $8.49.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Daxor stock. Keyes Stange & Wooten Wealth Management LLC grew its position in Daxor Co. (NASDAQ:DXR) by 34.8% in the third quarter, according to its most recent filing with the SEC. The fund owned 14,612 shares of the company’s stock after acquiring an additional 3,771 shares during the period. Keyes Stange & Wooten Wealth Management LLC owned 0.30% of Daxor worth $126,000 as of its most recent filing with the SEC. 1.34% of the stock is currently owned by institutional investors.

About Daxor

Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions.